Adverts

Open Access Articles- Top Results for Talnetant

Talnetant

</th></tr>
Talnetant
220px
Systematic (IUPAC) name
3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
Clinical data
Identifiers
174636-32-9 7pxY
None
PubChem CID 133090
IUPHAR ligand 2124
ChemSpider 117450 7pxN
UNII CZ3T9T146K 7pxY
Chemical data
Formula C25H22N2O2
382.454 g/mol
 14pxN (what is this?)  (verify)

Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome however its use as a potential antipsychotic drug for the treatment of schizophrenia has been discontinued.[1][2][3][4]

References

  1. ^ "UPDATE 1-GlaxoSmithKline prunes new drug pipeline". Reuters. Oct 15, 2007. 
  2. ^ Evangelista S. Talnetant GlaxoSmithKline. Current Opinion on Investigational Drugs. 2005 Jul;6(7):717-21. PMID 16044668
  3. ^ Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, Alpers DH, Dewit OE, Dukes GE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterology and Motility. 2007 Sep;19(9):732-43. PMID 17727393
  4. ^ Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J. In Vitro and In Vivo Characterization of the Non-peptide NK(3) Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. PMID 17728699


Lua error in package.lua at line 80: module 'Module:Buffer' not found.